Listeria infections associated with infliximab: case reports
作者： Thomas Kesteman , Jean-Cyr Yombi , Jacques Gigi , Patrick Durez
DOI: 10.1007/S10067-007-0660-8
关键词:
摘要: Infliximab is a human-murine chimeric monoclonal antibody directed against tumor necrosis factor alpha (TNFalpha). and other TNF blockers are used to treat inflammatory diseases such as rheumatoid arthritis (RA). suspected play key role in some infections. We report here two cases of Listeria monocytogenes sepsis associated with infliximab treatment for RA. The first patient developed terminal ileitis bacteraemia after three doses infliximab; the second RA presented prosthetic joint left hip, both related Listeria. Those occurred population 518 patients treated our hospitals since year 2000. events particular interest because severity infection, differs from infections, that, rheumatology unit, septic can mimic symptoms. They enhance likelihood this drug increase risk infections germs like
springer.com
academielouvain.be参考文章(15)
Lawrence A. Cone, Andrew O. Fitzmorris, Joel M. Hirschberg, Is Listeria monocytogenes an important pathogen for prosthetic joints Jcr-journal of Clinical Rheumatology. ,vol. 7, pp. 34- 37 ,(2001) , 10.1097/00124743-200102000-00008
Juan J. Gómez-Reino, Loreto Carmona, Vicente Rodríguez Valverde, Emilio Martín Mola, Maria Dolores Montero, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report Arthritis & Rheumatism. ,vol. 48, pp. 2122- 2127 ,(2003) , 10.1002/ART.11137
Nancy R. Slifman, Sharon K. Gershon, Jong-Hoon Lee, Evelyne T. Edwards, M. Miles Braun, Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents Arthritis & Rheumatism. ,vol. 48, pp. 319- 324 ,(2003) , 10.1002/ART.10758
Joseph Keane, Sharon Gershon, Robert P. Wise, Elizabeth Mirabile-Levens, John Kasznica, William D. Schwieterman, Jeffrey N. Siegel, M. Miles Braun, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent The New England Journal of Medicine. ,vol. 345, pp. 1098- 1104 ,(2001) , 10.1056/NEJMOA011110
C. E. Marculescu, E. F. Berbari, A. D. Hanssen, J. M. Steckelberg, S. W. Harmsen, J. N. Mandrekar, D. R. Osmon, Outcome of prosthetic joint infections treated with debridement and retention of components. Clinical Infectious Diseases. ,vol. 42, pp. 471- 478 ,(2006) , 10.1086/499234
S. T. Ooi, B. Lorber, Gastroenteritis Due to Listeria monocytogenes Clinical Infectious Diseases. ,vol. 40, pp. 1327- 1332 ,(2005) , 10.1086/429324
G. Schett, P. Herak, W. Graninger, J. S. Smolen, M. Aringer, Listeria-associated arthritis in a patient undergoing etanercept therapy : Case report and review of the literature Journal of Clinical Microbiology. ,vol. 43, pp. 2537- 2541 ,(2005) , 10.1128/JCM.43.5.2537-2541.2005
A. Chougle, V. Narayanaswamy, Delayed presentation of prosthetic joint infection due to Listeria monocytogenes. International Journal of Clinical Practice. ,vol. 58, pp. 420- 421 ,(2004) , 10.1111/J.1368-5031.2004.0040.X
S. Kroesen, Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. ,vol. 42, pp. 617- 621 ,(2003) , 10.1093/RHEUMATOLOGY/KEG263
Michel Malaise, B. Vander Cruyssen, A. Geldhof, Rene Westhovens, F. De Keyser, A. Peretz, Patrick Durez, F. Van den Bosch, N. Vastesaegere, L. Verbruggen, H. Mielants, L. De Clerck, Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect Annals of the Rheumatic Diseases. ,vol. 65, pp. 349- 349 ,(2006)